Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;46(5):462-7.
doi: 10.1093/jjco/hyw014. Epub 2016 Mar 13.

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Akira Inoue  1 , Kazushi Yoshida  2 , Satoshi Morita  3 , Fumio Imamura  4 , Takashi Seto  5 , Isamu Okamoto  6 , Kazuhiko Nakagawa  7 , Nobuyuki Yamamoto  8 , Satoshi Muto  9 , Masahiro Fukuoka  10
Affiliations

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Akira Inoue et al. Jpn J Clin Oncol. 2016 May.

Abstract

Background: The Japan Guidelines of Lung Cancer Therapy recommend epidermal growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent non-small cell lung cancer patients with epidermal growth factor receptor mutation. Although survival periods in recent reports of epidermal growth factor receptor-tyrosine kinase inhibitor treatment have been getting longer, the reasons why are unclear. We investigated the survival, prognostic factors and real-world treatment of non-small cell lung cancer patients with epidermal growth factor receptor mutation in clinical practice.

Methods: Non-small cell lung cancer patients (n = 1660) who started first-line treatment from January 2008 to December 2012 were enrolled. Patients were diagnosed with epidermal growth factor receptor mutation-positive advanced/recurrent non-small cell lung cancer by histology or cytology samples. The primary objective was to estimate overall survival. The secondary objectives were to determine prognostic factors, real-world treatment patterns and efficacy of gefitinib treatment. We calculated the treatment exposure rate for each treatment category using the following formula: exposure rate = person-years for the treatment category/total person-years × 100.

Results: The median overall survival was 30.8 months. Sex, age, histology, epidermal growth factor receptor mutation type, clinical stage and performance status affected overall survival. The exposure rates for all epidermal growth factor receptor-tyrosine kinase inhibitors, gefitinib and platinum-doublet chemotherapy were 62.1, 46.4 and 8.5% respectively. Overall 56.1% of patients were administered gefitinib as first-line therapy, and 39.0% were treated with ≥2 epidermal growth factor receptor-tyrosine kinase inhibitor regimens. The median progression-free survival in the first-line gefitinib group was 11.4 months. Factors affecting prognosis were sex, histology, clinical stage and performance status.

Conclusion: Epidermal growth factor receptor-tyrosine kinase inhibitors, especially gefitinib, are major components of the treatment regimens for epidermal growth factor receptor mutation-positive non-small cell lung cancer. Switching and re-challenging with epidermal growth factor receptor-tyrosine kinase inhibitors were also practiced in Japan.

Keywords: EGFR tyrosine kinase inhibitor; gefitinib; mutation; non-small cell lung cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival of all patients. CI, confidence interval.
See this image and copyright information in PMC

References

    1. The Japan Lung Cancer Society. Japan Guidelines of Lung Cancer Therapy. 2014 ed Japan: Kanehara Shuppan; 2014.
    1. Takano T, Fukui T, Ohe Y et al. . EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008;26:5589–95. - PubMed
    1. Inoue A, Kobayashi K, Maemondo M et al. . Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013;24:54–9. - PubMed
    1. Yoshioka H, Mitsudomi T, Morita S et al. . Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 2014;32:8117.
    1. Katakami N, Nishio M, Gotoh K et al. . Phase II trial to evaluate Erlotinib as a 1st line treatment to NSCLC with EGFR mutation: overall survival of JO22903. Haigan 2014;54:349.

MeSH terms

LinkOut - more resources